🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Global Challenge

Gonorrhoea infections are on the rise globally, with data suggesting more than 82 million instances each year. Particularly high rates are seen in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Data and Worldwide Availability

As per data published in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves two antibiotics. The trial included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Doctors treating patients have expressed hope. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.